As the U.S. stock market inches higher amid hopes for interest rate cuts, investors are closely monitoring economic indicators that could influence future Federal Reserve decisions. In this context, penny stocks—typically smaller or newer companies—remain a relevant investment area for those seeking unique opportunities outside the mainstream indices. While the term "penny stocks" might seem outdated, these investments can still offer significant value when backed by strong financials and growth potential.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.17 | $465.04M | ✅ 4 ⚠️ 0 View Analysis > |
| ATRenew (RERE) | $4.36 | $973.64M | ✅ 3 ⚠️ 1 View Analysis > |
| Waterdrop (WDH) | $1.81 | $654.61M | ✅ 4 ⚠️ 0 View Analysis > |
| VTEX (VTEX) | $4.09 | $744.23M | ✅ 3 ⚠️ 1 View Analysis > |
| WM Technology (MAPS) | $1.17 | $200.09M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.89 | $23.5M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.60 | $21.34M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.9699 | $7.04M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.29 | $97.2M | ✅ 3 ⚠️ 3 View Analysis > |
| TETRA Technologies (TTI) | $4.69 | $625.08M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 376 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Rapid Micro Biosystems (RPID)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Rapid Micro Biosystems, Inc. is a life sciences technology company that offers products for detecting microbial contamination in the manufacturing of pharmaceuticals, medical devices, and personal care products across various countries, with a market cap of $120.25 million.
Operations: The company's revenue of $30.29 million is derived from its Systems and Related LIMS Connection Software, Consumables, and Services segment.
Market Cap: $120.25M
Rapid Micro Biosystems, Inc. has seen its revenue increase to US$7.26 million for Q2 2025, up from US$6.62 million a year prior, while net losses have decreased to US$11.86 million from US$12.58 million in the same period. Despite being unprofitable and not expected to achieve profitability in the near term, it has reduced losses over five years at an annual rate of 8.1%. The company recently secured a five-year, $45 million loan facility aimed at supporting global commercial expansion and operational efficiencies of its Growth Direct system, enhancing its financial flexibility amidst high share price volatility and stable cash runway projections.
- Click to explore a detailed breakdown of our findings in Rapid Micro Biosystems' financial health report.
- Assess Rapid Micro Biosystems' future earnings estimates with our detailed growth reports.
Pliant Therapeutics (PLRX)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Pliant Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for fibrosis and related diseases, with a market cap of $114.18 million.
Operations: Pliant Therapeutics, Inc. does not report any revenue segments.
Market Cap: $114.18M
Pliant Therapeutics, Inc. is a pre-revenue biopharmaceutical company with a market cap of US$114.18 million, focused on fibrosis therapies. Despite being unprofitable and not expected to reach profitability in the next three years, it maintains a strong cash position with short-term assets of US$267.4 million exceeding liabilities significantly, offering a cash runway over two years if cash flow trends persist. Recent challenges include discontinuing bexotegrast development for idiopathic pulmonary fibrosis due to safety concerns and removal from several Russell indices, although it was added to the Russell Microcap Value Index reflecting its small-cap status amidst high share price volatility.
- Click here to discover the nuances of Pliant Therapeutics with our detailed analytical financial health report.
- Gain insights into Pliant Therapeutics' future direction by reviewing our growth report.
Gold Royalty (GROY)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Gold Royalty Corp. is a precious metals-focused royalty company that offers financing solutions to the metals and mining industry, with a market cap of $655.52 million.
Operations: The company's revenue is primarily derived from its investment in royalty and mineral stream interests, totaling $12.38 million.
Market Cap: $655.52M
Gold Royalty Corp. has shown revenue growth, reporting US$3.82 million in Q2 2025 compared to US$1.79 million a year ago, reducing its net loss to US$0.829 million from US$2.24 million the previous year. The company maintains a stable cash runway for over three years despite being unprofitable, supported by positive free cash flow and satisfactory debt levels with a net debt to equity ratio of 8.7%. Trading at 40% below estimated fair value, it benefits from an experienced management team and board but faces challenges with long-term liabilities exceeding short-term assets significantly.
- Take a closer look at Gold Royalty's potential here in our financial health report.
- Gain insights into Gold Royalty's outlook and expected performance with our report on the company's earnings estimates.
Turning Ideas Into Actions
- Embark on your investment journey to our 376 US Penny Stocks selection here.
- Seeking Other Investments? Uncover 10 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Pliant Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com